Method for treating alk-positive or ros1-positive non-small cell lung cancer
IL328396A0Pending Publication Date: 2026-07-01SHENZHEN TARGETRX INC
0 Cites 0 Cited by
Patent Information
- Application Number
- IL328396
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-05
- Filing Date
- 2024-11-14
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
The prior art is difficult to effectively treat ALK-positive or ROS1-positive non-small cell lung cancer, especially in cases where there is no response or drug resistance to the previous treatment.
Method used
Targeted therapy is achieved by oral administration against ALK-positive and ROS1-positive non-small cell lung cancer, especially in advanced and CNS metastatic cases using Compound A or a pharmaceutically acceptable salt thereof.
Benefits of technology
Compound A showed an efficient inhibitory ability to ALK and ROS1, which can effectively inhibit the growth and division of non-small cell lung cancer cells, and prolong the patient's survival and free progression period.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided is a method for treating ALK-positive non-small cell lung cancer in a subject by means of administering a compound A or a pharmaceutically acceptable salt thereof to the subject. Further provided is a method for treating ROS1-positive non-small cell lung cancer in a subject by means of administering compound A or a pharmaceutically acceptable salt thereof to the subject.
Need to check novelty before this filing date? Find Prior Art